A molecular compound developed by Saint Louis University scientists restored learning, memory and appropriate behavior in a mouse model of Alzheimer’s disease, according to findings in the May issue of the Journal of Alzheimer’s Disease.
The molecule also reduced inflammation in the part of the brain responsible for learning and memory.
The paper, authored by a team of scientists led by Susan Farr, Ph.D., research professor of geriatrics at Saint Louis University, is the second mouse study that supports the potential therapeutic value of an antisense compound in treating Alzheimer’s disease in humans.
“It reversed learning and memory deficits and brain inflammation in mice that are genetically engineered to model Alzheimer’s disease,” Farr said. “Our current findings suggest that the compound, which is called antisense oligonucleotide (OL-1), is a potential treatment for Alzheimer’s disease.”
Farr cautioned that the experiment was conducted in a mouse model. Like any drug, before an antisense compound could be tested in human clinical trials, toxicity tests need to be completed.
The Latest on: Alzheimer’s
via Google News
The Latest on: Alzheimer’s
- Research suggests specialized brain imaging can unveil mysteries of Alzheimer’s disease, other disorderson May 12, 2022 at 9:17 am
Alzheimer’s disease is the most common form of dementia, one of the major causes of dependency and disability in older adults. Though advances have been made in understanding the harrowing brain ...
- Spinal fluid from young animals and people could help treat Alzheimer's, study findson May 12, 2022 at 9:09 am
The memory of aging mice improved when they received a substance found in the spinal fluid of young animals and people.
- How Medicare covers Alzheimer's diseaseon May 12, 2022 at 8:45 am
Dear Savvy Senior, What exactly does Medicare cover when it comes to Alzheimer’s disease? My husband was recently diagnosed with early-stage Alzheimer’s, and we would like to find out what’s ...
- The added burden of young onset Alzheimer's diseaseon May 12, 2022 at 8:00 am
People diagnosed with Alzheimer's disease at a younger age will experience faster symptom progression than their older counterparts, a new study has found, potentially causing their support ...
- Healthy habits may improve longevity, prevent Alzheimer's diseaseon May 12, 2022 at 7:50 am
They also spent more of their remaining years without Alzheimer's disease. "We evaluated these lifestyle factors in combination because they may have synergistic effects on dementia risk," says ...
- Dementia: Combination of “feelings” and measurements suggest Alzheimer’s in the early stageon May 12, 2022 at 6:17 am
Subjective memory disorders in conjunction with conspicuous levels of beta-amyloid proteins in the cerebrospinal fluid are a strong indication of developing Alzheimer’s disease. This is the conclusion ...
- Disc golf fundraiser to benefit Alzheimer's Association at Deer Lakes Parkon May 12, 2022 at 6:01 am
A Penn Hills woman is working to honor her late mother and raise awareness of Alzheimer’s disease, an illness she said is widely misunderstood. “It’s not an old person’s thing,” Amy ...
- Daytime Napping in Seniors May Signal Dementia / Alzheimer’s Diseaseon May 12, 2022 at 5:25 am
Daytime sleep duration triples after Alzheimer's diagnosis, UCSF-Harvard led study shows. Daytime napping in the elderly is a normal part of aging, but it may also foreshadow Alzheimer's disease and ...
- Alzheimer's Association holding two forums to get intel on local dementia careon May 12, 2022 at 12:28 am
The local Alzheimer's Association would like your feedback. Have you or someone you know been impacted by Alzheimer’s or dementia? If so, the organization invites you to one of two community ...
- Bothell biotech firm and activist investor feud over control of Alzheimer’s researchon May 11, 2022 at 5:14 pm
An investor claiming Athira Pharma didn’t disclose allegations of research misconduct by a co-founder when it raised $204 million in a 2020 IPO.
via Bing News